MDXG vs. NARI, NVST, PRCT, IRTC, WRBY, LIVN, ENOV, NVCR, TMDX, and LMAT
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
MiMedx Group vs.
MiMedx Group (NASDAQ:MDXG) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
MiMedx Group has higher earnings, but lower revenue than Inari Medical. Inari Medical is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Inari Medical received 21 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 81.82% of users gave MiMedx Group an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
In the previous week, Inari Medical had 7 more articles in the media than MiMedx Group. MarketBeat recorded 8 mentions for Inari Medical and 1 mentions for MiMedx Group. Inari Medical's average media sentiment score of 0.54 beat MiMedx Group's score of 0.00 indicating that Inari Medical is being referred to more favorably in the news media.
79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 91.0% of Inari Medical shares are owned by institutional investors. 1.3% of MiMedx Group shares are owned by company insiders. Comparatively, 10.6% of Inari Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MiMedx Group has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
MiMedx Group has a net margin of 23.86% compared to Inari Medical's net margin of -13.68%. MiMedx Group's return on equity of 26.21% beat Inari Medical's return on equity.
MiMedx Group presently has a consensus target price of $12.00, suggesting a potential upside of 50.38%. Inari Medical has a consensus target price of $68.00, suggesting a potential downside of 14.97%. Given MiMedx Group's stronger consensus rating and higher possible upside, research analysts clearly believe MiMedx Group is more favorable than Inari Medical.
Summary
MiMedx Group beats Inari Medical on 11 of the 18 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
This page (NASDAQ:MDXG) was last updated on 2/22/2025 by MarketBeat.com Staff
